The continuous effect of tyrosine kinase inhibitor on idiopathic pulmonary was newly found and the effect can last about two years to slow the progression of idiopathic pulmonary (IPF), which is a breakthrough finding for the treatment of the disease that has no cure way was found for at present.
Earlier in 2014, the FDA approved tyrosine kinase inhibitor-nintedanib on IPF treatment for its efficacy on the treatment of IPF. Before the approval, experiments were conducted. A 12-month phase 2 trial was carried out by scientists, in which 432 people were designed to and they took one of four different doses of the drug or a corresponding amount of placebo. And the experiment showed an improvement on the FVC decline on the patient group who took 150mg twice daily than its placebo group.
Then researchers conducted twice phase 3 trials with a time span of 52 weeks, and both showed a positive effect of nintedanib on improving the condition of IPF with side effects of diarrhea and only 5% patients suffered from a discontinuation on the drug for serious side effects. In the two phases of experiments, the safety and efficacy of the tyrosine kinase inhibitor were proved.
The recent new finding of tyrosine kinase inhibitor is about the effect lasting time on the base of the ensured safety and effect. Scientists found that nintedanib treatment on IPF can last as long as two years with a detected FVC decline. This discovery is quite significant for the development of IPF treatment as the disease needs continuous treatment to slow the progression. Besides IPF is a relatively rare disease, drugs and other forms of advanced medication still need research effort to be developed. Thus the new finding drives an efficient research direction on the present medication situation of IPV and also provides better insight into the disease itself.
Idiopathic Pulmonary Fibrosis Medication from Medscape (Aug 12, 2015)
Tyrosine Kinase Inhibitor Slows Progression of Idiopathic Pulmonary Fibrosis from Medicalresearch (October 12, 2015)